• Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy

Browse Tag

SignalRx Pharmaceuticals Inc

New collaboration to develop an inhalable SF2523 for lung cancer, lung fibrosis and SARS-CoV-2
August 28, 2021
Pharmaceutical News

New collaboration to develop an inhalable SF2523 for lung cancer, lung fibrosis and SARS-CoV-2

SignalRx Pharmaceuticals Inc., Crystec Ltd., and ADYA Consulting SAGL are pleased toannounce a new collaboration to develop an inhaled dry powder formulation of SF2523 for the treatmentof pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses. SignalRx SF2523 is a novel, small molecule dual PI3K-BRD4

More
New collaboration to develop an inhalable SF2523 for lung cancer, lung fibrosis and SARS-CoV-2
Pharmaceutical News

New collaboration to develop an inhalable SF2523 for lung cancer, lung fibrosis and SARS-CoV-2

August 28, 2021

SignalRx Pharmaceuticals Inc., Crystec Ltd., and ADYA Consulting SAGL are pleased toannounce a new collaboration to develop an inhaled dry

More
  • Can You Sue Your Doctor for Blindness Caused by Elmiron®?
  • Experts advise European SME packaging firms to expand or seek acquisition prior to Pharmapack Europe
  • FIP advances sustainable health systems by providing new guidance for self-managing reflux symptoms
  • APAC overview: trends, challenges, and possibilities for growth in the MarTech sector
  • Modernizing Therapeutic Cell Production

© 2010-2022 PharmaMirror.com - All Rights Reserved.

  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
  • Home
  • Articles
  • Global News
  • Interest
  • Health Tips
  • Write for Us
    • Contact Us
      • About
      • Privacy Policy
Go toTop